Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEkf Diagnostics Regulatory News (EKF)

Share Price Information for Ekf Diagnostics (EKF)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 28.80
Bid: 28.80
Ask: 30.70
Change: -1.90 (-6.19%)
Spread: 1.90 (6.597%)
Open: 28.80
High: 28.80
Low: 28.80
Prev. Close: 30.70
EKF Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

19 Jan 2016 14:44

RNS Number : 3442M
EKF Diagnostics Holdings PLC
19 January 2016
 

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES

 

 

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached:

 

EKF Diagnostic Holdings Plc

2. Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

Yes

 

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached.

 

 

 

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

 

 

An event changing the breakdown of voting rights

 

Other (please specify):

 

 

 

3. Full name of person(s) subject to thenotification obligation:

Legal & General Group Plc (L&G)

4. Full name of shareholder(s) (if different from 3.):

 

Legal & General Assurance Society Limited (LGAS & LGPL)

 

 

5. Date of the transaction and date onwhich the threshold is crossed orreached:

 

15 January 2016

6. Date on which issuer notified:

19 January 2016

7. Threshold(s) that is/are crossed orreached:

 

L&G (From 5% to 4%)

     
 

 

8. Notified details:

 

A: Voting rights attached to shares

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

 

Numberof shares

Number of votingrights

% of voting rights

Direct

Indirect

Direct

Indirect

Ordinary 1p

25,091,376

 

(As on 22/04/2014)

 19,214,079

 19,214,079

-

4.55%

-

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financialinstrument

 

Expirationdate

 

Exercise/Conversion Period

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

 

% of votingrights

 

 

 

 

 

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financialinstrument

 

 

Exercise price

 

Expiration date

 

Exercise/Conversion period

 

Number of voting rights instrument refers to

 

 

% of voting rights

 

 

 

 

 

 

 

Nominal

Delta

 

 

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

 

 19,214,079

 

4.55%

                 
 

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable:

 

Legal & General Group Plc (Direct and Indirect) (Group) (32,704,079, 7.74% = Total Position)

 

Legal & General Investment Management (Holdings) Limited (LGIMH) (Direct and Indirect) (32,704,079, 7.74% = Total Position)

 

Legal & General Investment Management Limited (Indirect) (LGIM) (32,704,079, 7.74% = Total Position)

 

Legal & General Group Plc (Direct) (L&G) (19,214,079, 4.55% = LGAS, LGPL & PMC)

Legal & General Investment Management (Holdings) Limited (Direct) (LGIMHD)

Legal & General Insurance Holdings Limited (Direct) (LGIH) (19,214,079, 4.55% = LGAS & LGPL)

Legal & General Assurance (Pensions Management) Limited (PMC)

Legal & General Assurance Society Limited (LGAS & LGPL) (19,214,079, 4.55% = LGAS & LGPL)

 

Legal & General Pensions Limited (Direct) (LGPL)

   

 

 

Proxy Voting:

10. Name of the proxy holder:

N/A

11. Number of voting rights proxy holder will ceaseto hold:

N/A

12. Date on which proxy holder will cease to holdvoting rights:

N/A

 

13. Additional information:

Notification using the total voting rights figure of 422,057,074

14. Contact name:

Amy Williams (LGIM)

15. Contact telephone number:

029 2035 4097

   

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUKSSRNRAAAAR
Date   Source Headline
20th May 20147:01 amRNSAGM Statement
20th May 20147:00 amRNSSelah to provide Women's Health testing services
19th May 20143:13 pmRNSHolding(s) in Company - Replacement
16th May 20144:35 pmRNSHolding(s) in Company
15th May 20147:00 amRNSDirector/PDMR Shareholding
8th May 20141:10 pmRNSDirector/PDMR Shareholding
7th May 20147:00 amRNSSelah update
30th Apr 20147:01 amRNSHolding(s) in Company
23rd Apr 20144:46 pmRNSHolding(s) in Company
23rd Apr 20143:33 pmRNSHolding(s) in Company
17th Apr 20141:13 pmRNSDirector/PDMR Shareholding
15th Apr 20147:00 amRNSInvestor Teach-In
11th Apr 201411:33 amRNSResults of General Meeting and Total Voting Rights
10th Apr 20149:33 amRNSResult of Offer
31st Mar 20144:46 pmRNSDirector Resignation
31st Mar 201410:01 amRNSHolding(s) in Company
26th Mar 20144:18 pmRNSHolding(s) in Company
24th Mar 20147:00 amRNSHolding(s) in Company Replacement
20th Mar 201411:26 amRNSResult of the Placing
20th Mar 20147:00 amRNSProposed Acquisitions, Placing & Offer
12th Mar 20147:00 amRNSAcquisition of Separation Technology, Inc.
4th Mar 201411:16 amRNSTransfer of production
26th Feb 20147:00 amRNSFinal Results
18th Feb 20147:00 amRNSQuo-Lab registration in Mexico
17th Feb 20147:00 amRNSNotice of Results
28th Jan 201412:21 pmRNSAdditional Listing
27th Jan 20147:00 amRNSYear end trading update
24th Jan 20147:00 amRNSHolding(s) in Company
20th Jan 20147:00 amRNSPointMan enriches low-level mutations from blood
19th Nov 20137:00 amRNSAcute Kidney Injury marker development
4th Nov 20137:00 amRNSNew PointManT DNA enrichment products launched
30th Oct 20133:10 pmRNSHolding(s) in Company
8th Oct 20138:25 amRNSHolding(s) in Company
3rd Oct 20139:03 amRNSChange of Registered Office
25th Sep 201311:34 amRNSHolding(s) in Company
19th Sep 20137:28 amRNSInvestor Results Briefing
16th Sep 20137:00 amRNSInterim Results
14th Aug 20137:00 amRNSInvestor Teach-In
1st Aug 20137:00 amRNSTrading update
25th Jul 20137:00 amRNSInvestor Teach-In
23rd Jul 20137:00 amRNSSenior management update
4th Jul 201312:09 pmRNSHolding(s) in Company
26th Jun 20135:43 pmRNSAnalyst & Investor Teach-In
18th Jun 201310:17 amRNSDirector Share Transfer
11th Jun 20133:52 pmRNSAmendment to Long-Term Incentive Plan
15th May 20134:34 pmRNSResult of AGM
15th May 20137:00 amRNSAGM Statement
13th May 20137:00 amRNSFirst PointMan DNA enrichment products launched
15th Apr 20131:34 pmRNSPublication of Annual Report & Notice of AGM
18th Mar 20137:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.